Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS opened at $0.10 on Monday. The company has a market capitalization of $4.31 million, a P/E ratio of -0.01 and a beta of 1.51. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The business’s 50 day simple moving average is $0.05 and its 200-day simple moving average is $0.30.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.